PharmaShots | Incisive News in 3 Shots

Subscribe Now

biohaven

Biohaven Acquires Rights for BHV-8000 to Treat Immune-Mediated Brain Disorders

Biohaven Acquires Rights for BHV-8000 to Treat Immune-Mediated Brain Disorders

March 23, 2023

Biohaven to Acquire Channel Biosciences for ~$3B

Biohaven to Acquire Channel Biosciences for ~$3B

February 28, 2022

Biohaven Entered into an Exclusive License and Research Agreement with KU Leuven to Develop and Commercialize BHV-2100 for Chronic Pain Disorders

Biohaven Entered into an Exclusive License and Research Agreement with KU Leuven to Develop and Commercialize BHV-2100 for Chronic...

January 10, 2022

Biohaven Reports Results of Zavegepant in P-III Study for the Treatment of Migraine

Biohaven Reports Results of Zavegepant in P-III Study for the Treatment of Migraine

December 7, 2021

PharmaShots Weekly Snapshots (November 08, 12, 2021)

PharmaShots Weekly Snapshots (November 08, 12, 2021)

November 12, 2021

PharmaShots Weekly Snapshots (May 31 - June 4, 2021)

PharmaShots Weekly Snapshots (May 31 - June 4, 2021)

June 4, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us